MYGN Similar Chart Price Prediction
The price of MYGN is predicted to go up -11.02%, based on the high correlation periods with WLK. The similarity of these two price pattern on the periods is 94.98%.
MYGN
WLK
Down: -11.02%Similarity: 94.98%
MYGN Revenue Forecast
MYGN EPS Forecast
MYGN FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
MYGN VS S&P500
Myriad is gaining payer coverage for GeneSight, and its aggressive salesforce expansion plan increases testing volume and sales.
Synergies among the company's newer products could unfold, helping to diversify Myriad's revenue stream outside of hereditary cancer testing.
Myriad's extensive proprietary database for MyRisk could enable the company to hold on to its market share and maintain durable price premiums.
MYGN Analyst's Forecast
Lu Li
UBS
Hold
Price Target
$18
Upside
+17.34%
UBS initiated coverage of Myriad Genetics with a Neutral rating and $18 price target. The analyst believes Myriad's growth profile has improved versus historical trends, but says GeneSight reimbursement remains a stock overhang in the near term. It continues to see growth momentum in hereditary cancer and prenatal businesses, but expects the company's total revenue growth to normalize at high single-digits beyond 2025 versus management expectations of double-digits as tailwinds from competitors exiting the market should end by 2025.
Puneet Souda
Leerink Partners
Buy → Hold
Price Target
$30 → $21
Upside
+41.13%
Tejas Savant
Morgan Stanley
Hold
Price Target
$32 → $21
Upside
+37.98%